A global first — a continuously learning reference index built from living human biology.

The PK Index captures how diverse populations absorb, metabolize, and respond to drugs — creating a real-world foundation for precision dosing and safer, more effective therapeutics.

​

A Living Pharmacokinetic Atlas

Every Bio-Avatar within the PBLO biobank contributes live data on how cells and tissues process compounds — from absorption and metabolism to toxicity and clearance.

By aggregating these signals across thousands of organoids representing distinct demographics, the PK Index builds a dynamic map of how real populations handle medicine.

It replaces static, limited clinical datasets with continuously refreshed biological insight — a living atlas of human pharmacology.

​

Precision Dosing by Demographic

Traditional PK studies rely on small, often homogeneous trial groups — ignoring the genetic, metabolic, and environmental factors that shape how drugs behave in different bodies.
The PK Index corrects that blind spot by modelling the diversity of entire populations.

​

This enables the fine-tuning of drug design and dosing for age, sex, ancestry, and comorbidities — ensuring every therapy performs safely and effectively in the people it’s meant to serve.

 

AI-Driven Drug Optimization 

Powered by the PBLO data engine, the PK Index trains AI models that can predict how a new or existing molecule will behave across populations — before human trials begin.

This insight allows pharmaceutical partners to:

• Optimize formulation and delivery.

• Reduce trial failure rates.

• Design population-specific generics and biosimilars.

• Fast-track drug approvals through predictive validation.

 

Sovereign Health Intelligence

Hosted within sovereign infrastructure, the PK Index allows nations to generate and own their own pharmacokinetic data.
It underpins a new form of pharmacoequity — where regulatory decisions, clinical guidelines, and reimbursement models are grounded in the biology of local populations, not imported assumptions.

​

The result: safer medicine, stronger sovereignty, and a future where precision dosing is a national capability.